Abstract
BackgroundApproximately 30–40% of AML patients relapse following allogeneic hematopoietic stem cell transplant therapy, leaving them with very few treatment options.1 2 Rare patients that naturally develop an HA-1-specific graft-versus-leukemia T...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have